Celgene, say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger

With the Federal Trade Commission (FTC) sweating the details of Bristol-Myers Squibb and Celgene’s proposed $74 billion merger, all eyes were on the companies’ combined psoriasis portfolio, which regulators feared would corner the market. The feds found a solution: You can have your merger, but you don’t get to keep Celgene's blockbuster Otezla.
Read more...

;